PATIENT GUIDE
Clinical trials progress through four phases before a treatment is approved. Each phase answers different questions about safety, dosage, and effectiveness. Most patients can enroll in Phase 2 and Phase 3 trials.
Informational only. Not medical advice. Always consult a qualified healthcare professional before making decisions about clinical trial participation.
Phase 1 trials are the first time a treatment is tested in humans. They typically enroll 20–80 participants — often healthy volunteers or patients with advanced disease who have exhausted other options. The goal is to establish safe dosage ranges and identify side effects. Phase 1 trials are not about proving the treatment works.
Phase 2 trials expand to 100–300 participants with the condition being studied. They test whether the treatment actually works and continue to assess safety. Some Phase 2 trials are randomized — participants may receive the experimental treatment or a control. This is where most promising treatments are confirmed or ruled out.
Phase 3 trials are large — typically 1,000–3,000 participants across multiple sites. They compare the new treatment to the current standard of care. Most participants are randomly assigned to receive either the new treatment or the existing standard treatment. FDA approval is typically based on Phase 3 results.
Phase 4 trials happen after a treatment is already approved and on the market. They monitor long-term safety and effectiveness in real-world populations, and may test the treatment in new groups (e.g., children, elderly patients). Participation in Phase 4 trials carries lower experimental risk.
Phase 2 and Phase 3 trials offer the best balance of access to potentially effective treatments and manageable risk. Phase 3 trials in particular are well-validated — the treatment has already shown promise in Phase 2. Phase 1 trials carry more uncertainty and are typically reserved for patients with no other options.
COMMON QUESTIONS
Which phase is safest to participate in?
Phase 3 and Phase 4 trials are generally considered the safest, as the treatment has already been tested in earlier phases. Phase 1 carries the most uncertainty.
Do Phase 2 trials work?
Historically, about 30–40% of treatments that enter Phase 2 eventually receive approval. Phase 2 is a significant filter — many treatments that show early promise don't pan out at scale.
Why would a trial be stopped early?
Trials can stop early for safety reasons (unexpected harm), efficacy reasons (the treatment clearly works ahead of schedule), or futility (it clearly won't meet its endpoint). All three outcomes are possible.
Is Phase 1 only for very sick patients?
Not always. Some Phase 1 trials recruit healthy volunteers to study safety in people without the disease. Others focus on patients with advanced disease who have no other options.
Ready to find a trial?
Search thousands of recruiting clinical trials by condition and location.
FIND TRIALS →